Annual Drug Patent Expirations for INCRUSE+ELLIPTA Incruse Ellipta is a drug marketed by Glaxo Grp England and is included in one NDA. It is available from one supplier. There are…
The post New patent for Glaxo Grp drug INCRUSE ELLIPTA appeared first o…
This chart shows the pharmaceutical companies with the most patents in South Korea. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…
The post Which pharmaceutical companies have the most drug pat…
Which pharmaceutical companies have the most drug patents in South Korea? Read Post »
Switching pharmaceutical excipients, the inactive components used in drug formulations, can have significant implications for both production costs and market appeal. These components, while not contributing directly to the therapeutic…
The post Cost-C…
Cost-Cut Without Compromise: Navigating Excipient Switching in Pharma Read Post »
Annual Drug Patent Expirations for NASCOBAL Nascobal is a drug marketed by Par Pharm and Endo Pharms Inc and is included in two NDAs. It is available from one supplier.…
The post New patent expiration for Endo Pharms drug NASCOBAL appeared first on Dru…
New patent expiration for Endo Pharms drug NASCOBAL Read Post »
Annual Drug Patent Expirations for GRALISE Gralise is a drug marketed by Almatica and is included in one NDA. It is available from one supplier. There is one patent protecting…
The post New patent expiration for Almatica drug GRALISE appeared first on …
This chart shows the pharmaceutical companies with the most patents in Serbia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…
The post Which pharmaceutical companies have the most drug paten…
Which pharmaceutical companies have the most drug patents in Serbia? Read Post »
This chart shows the companies which have received the most New Combination exclusivities in the past five years. New Combinations are one of the categories for which the FDA grants…
The post Pharmaceutical companies with the most ‘New Combination’ dru…
Pharmaceutical companies with the most ‘New Combination’ drugs Read Post »
Annual Drug Patent Expirations for AUVI-Q Auvi-q is a drug marketed by Kaleo Inc and is included in one NDA. It is available from three suppliers. There are twenty-four patents…
The post New patent for Kaleo Inc drug AUVI-Q appeared first on DrugPatent…
Annual Drug Patent Expirations for AVYCAZ Avycaz is a drug marketed by Allergan and is included in one NDA. It is available from one supplier. There are seven patents protecting…
The post New patent for Allergan drug AVYCAZ appeared first on DrugPatent…
Annual Drug Patent Expirations for ANJESO Anjeso is a drug marketed by Baudax and is included in one NDA. There are seven patents protecting this drug. Drug patent litigation for…
The post New patent expiration for Baudax drug ANJESO appeared first on …
Get new actionable insights and updates from BiotechBlog
